



New Preclinical Data for EDP-235, Enanta's Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022

September 7, 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 7, 2022-- [Enanta Pharmaceuticals, Inc.](#) (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the treatment of COVID-19, will be presented at IDWeek 2022 being held October 19 – 23, 2022 in Washington, DC.

Oral Presentation

Date: Friday, October 21, 2022

Time: 12:15 – 12:45 PM ET

Session Title: Rapid Fire Poster Session: COVID-19 Clinical Issues

Session Location: Walter E. Washington Convention Center, Exhibit Hall BC, Hot Zone Arenas

Presentation Title: "EDP-235, A Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes, with the Potential for Mitigation of Cytokine Storm in High-Risk COVID-19 Patients"

Presenter: Li-Juan Jiang, Ph.D.

Poster Presentation

Date: Friday, October 21, 2022

Time: 12:15 – 1:30 PM ET

Session Title: COVID-19: Treatment

Session Location: Walter E. Washington Convention Center, Exhibit Hall BC

Poster #1123: "EDP-235, A Potent and Once-Daily Oral Antiviral, Demonstrates Excellent Penetration into Macrophages and Monocytes, with the Potential for Mitigation of Cytokine Storm in High-Risk COVID-19 Patients"

Presenter: Li-Juan Jiang, Ph.D.

Posters will be available to view on the conference platform during the conference. Further information about IDWeek 2022 can be found [here](#).

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta's research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220907005418/en/): <https://www.businesswire.com/news/home/20220907005418/en/>

Media and Investors

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.